{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:02:47Z","timestamp":1784757767809,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Megakaryocytes, the platelet precursors, have been known to populate tissues other than the bone marrow, most prominently the lung, but also the liver and spleen. Work in myeloproliferative neoplasms has established that dysplastic megakaryocytes are central organisers of the fibrosis in the bone marrow. In this commentary, we frame a hypothesis-gathering question as to whether megakaryocytes might analogously act as context-dependent contributors to organ fibrosis outside the marrow. In the lung, studies have identified resident\/trafficking megakaryocytes with inflammatory properties, while in the liver, megakaryocytes-rich extramedullary foci often co-localise with periportal and perisinusoidal fibrosis. Approved agents for idiopathic pulmonary fibrosis act on broad growth-factor pathways across multiple cell types that may overlapwith the megakaryocytes\/platelet secretome. It is thus possible that megakaryocytes may play a contributory role in organ fibrosis. We acknowledge that these observations are associative and preclinical, and that established epithelial-mesenchymal mechanisms remain central in organ fibrosis. We therefore do not assert that megakaryocytes are contributors of organ fibrosis. Rather, we pose this as a testable question prompted by converging yet incomplete evidence.<\/jats:p>","DOI":"10.1093\/qjmed\/hcag031","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:41:56Z","timestamp":1769172116000},"page":"455-458","source":"Crossref","is-referenced-by-count":0,"title":["Do megakaryocytes contribute to organ fibrosis?"],"prefix":"10.1093","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0808-8779","authenticated-orcid":false,"given":"Gerard","family":"Gurumurthy","sequence":"first","affiliation":[{"name":"The Queen Elizabeth Hospital Kings Lynn NHS Foundation Trust , Kings Lynn,","place":["UK"]},{"name":"Addenbrooke\u2019s Hospital, Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7218-0993","authenticated-orcid":false,"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[{"name":"MAHSC Professor, The University of Manchester , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026072217472702200_hcag031-B1","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.rpth.2023.100053","article-title":"Megakaryocytes in the lung: history and future perspectives","volume":"7","author":"Livada","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026072217472702200_hcag031-B2","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.3390\/jcm10245831","article-title":"Extramedullary hematopoiesis of the liver and spleen","volume":"10","author":"Cenariu","year":"2021","journal-title":"J Clin Med"},{"key":"2026072217472702200_hcag031-B3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.5858\/arpa.2013-0018-OA","article-title":"Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F","volume":"138","author":"Vytrva","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"2026072217472702200_hcag031-B4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/j.seminhematol.2010.03.001","article-title":"Megakaryopoiesis","volume":"47","author":"Geddis","year":"2010","journal-title":"Semin Hematol"},{"key":"2026072217472702200_hcag031-B5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2021010697","article-title":"Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis","volume":"138","author":"Sun","year":"2021","journal-title":"Blood"},{"key":"2026072217472702200_hcag031-B6","first-page":"1500","article-title":"New insights into the generation and function of megakaryocytes in health and disease","volume":"110","author":"Du","year":"2025","journal-title":"Haematologica"},{"key":"2026072217472702200_hcag031-B7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3960\/jslrt.18006","article-title":"Histological evaluation of myeloproliferative neoplasms","volume":"58","author":"Fujiwara","year":"2018","journal-title":"J Clin Exp Hematop"},{"key":"2026072217472702200_hcag031-B8","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.ajpath.2017.03.009","article-title":"Megakaryocytes in myeloproliferative neoplasms have unique somatic mutations","volume":"187","author":"Guo","year":"2017","journal-title":"Am J Pathol"},{"key":"2026072217472702200_hcag031-B9","doi-asserted-by":"crossref","first-page":"e2018068","DOI":"10.4084\/mjhid.2018.068","article-title":"Megakaryocyte contribution to bone marrow fibrosis: many arrows in the quiver","volume":"10","author":"Malara","year":"2018","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"2026072217472702200_hcag031-B10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.1989.tb04310.x","article-title":"Transforming growth factor-\u03b2 regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts","volume":"72","author":"Kimura","year":"1989","journal-title":"Br J Haematol"},{"key":"2026072217472702200_hcag031-B11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.1991.tb07952.x","article-title":"Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-\u03b2 in patients with myelofibrosis with myeloid metaplasia","volume":"77","author":"Martyr\u00e9","year":"1991","journal-title":"Br J Haematol"},{"key":"2026072217472702200_hcag031-B12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.hoc.2020.11.004","article-title":"The role of megakaryocytes in myelofibrosis","volume":"35","author":"Melo-Cardenas","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026072217472702200_hcag031-B13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature21706","article-title":"The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors","volume":"544","author":"Lefran\u00e7ais","year":"2017","journal-title":"Nature"},{"key":"2026072217472702200_hcag031-B14","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1016\/j.jtha.2025.09.002","article-title":"Platelets as evolution\u2019s answer to both hemorrhage and infection","volume":"23","author":"Gurumurthy","year":"2025","journal-title":"J Thromb Haemost"},{"key":"2026072217472702200_hcag031-B15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1055\/s-0040-1714274","article-title":"Pulmonary megakaryocytes in coronavirus disease 2019 (COVID-19): roles in thrombi and fibrosis","volume":"46","author":"Thachil","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"2026072217472702200_hcag031-B16","doi-asserted-by":"crossref","first-page":"1029223","DOI":"10.3389\/fimmu.2022.1029223","article-title":"Occurrence and role of lung megakaryocytes in infection and inflammation","volume":"13","author":"Gelon","year":"2022","journal-title":"Front Immunol"},{"key":"2026072217472702200_hcag031-B17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.33549\/physiolres.935477","article-title":"The lung is not a primary site of platelet biogenesis","volume":"74","author":"Ye","year":"2025","journal-title":"Physiol Res"},{"key":"2026072217472702200_hcag031-B18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41419-019-1903-8","article-title":"Megakaryocytes participate in the occurrence of bleomycin-induced pulmonary fibrosis","volume":"10","author":"Zhou","year":"2019","journal-title":"Cell Death Dis"},{"key":"2026072217472702200_hcag031-B19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3858\/emm.2010.42.6.048","article-title":"Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis","volume":"42","author":"Song","year":"2010","journal-title":"Exp Mol Med"},{"key":"2026072217472702200_hcag031-B20","doi-asserted-by":"crossref","first-page":"e0151765","DOI":"10.1371\/journal.pone.0151765","article-title":"Impact of a CXCL12\/CXCR4 antagonist in bleomycin (BLM) induced pulmonary fibrosis and carbon tetrachloride (CCl4) induced hepatic fibrosis in mice. Mukhopadhyay P, editor","volume":"11","author":"Chow","year":"2016","journal-title":"PLoS One"},{"key":"2026072217472702200_hcag031-B21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1172\/JCI200420997","article-title":"Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis","volume":"114","author":"Phillips","year":"2004","journal-title":"J Clin Invest"},{"key":"2026072217472702200_hcag031-B22","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1513\/AnnalsATS.201410-448MG","article-title":"Mechanisms of alveolar epithelial injury, repair, and fibrosis","volume":"12","author":"Chambers","year":"2015","journal-title":"Ann Am Thorac Soc."},{"key":"2026072217472702200_hcag031-B23","doi-asserted-by":"crossref","first-page":"L487","DOI":"10.1152\/ajplung.00227.2022","article-title":"Investigating the role of platelets and platelet-derived transforming growth factor-\u03b2 in idiopathic pulmonary fibrosis","volume":"325","author":"Chong","year":"2023","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026072217472702200_hcag031-B24","doi-asserted-by":"crossref","first-page":"e235064","DOI":"10.1136\/bcr-2020-235064","article-title":"Extramedullary haematopoiesis presenting as a periportal mass","volume":"13","author":"Rafiee","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2026072217472702200_hcag031-B25","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.radcr.2025.02.006","article-title":"Periportal extramedullary hematopoiesis in a patient with primary myelofibrosis: a great mimicker of an infiltrating tumor in the liver","volume":"20","author":"Crawford","year":"2025","journal-title":"Radiol Case Rep"},{"key":"2026072217472702200_hcag031-B26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"2026072217472702200_hcag031-B27","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-04-846626","article-title":"A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis","volume":"132","author":"Masarova","year":"2018","journal-title":"Blood"},{"key":"2026072217472702200_hcag031-B28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026072217472702200_hcag031-B29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/medicina59050999","article-title":"Drug-induced thrombocytopenia due to nintedanib during treatment of idiopathic pulmonary fibrosis","volume":"59","author":"Dumic","year":"2023","journal-title":"Medicina (Mex)"},{"key":"2026072217472702200_hcag031-B30","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcag031\/66799732\/hcag031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/119\/6\/455\/66799732\/hcag031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/119\/6\/455\/66799732\/hcag031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:47:34Z","timestamp":1784756854000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/119\/6\/455\/8466460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcag031","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,28]]}}}